Estimated Effect of Inactivated Poliovirus Vaccine Campaigns, Nigeria and Pakistan, January 2014–April 2016

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Shirreff, George ; Wadood, Mufti Zubair ; Vaz, Rui Gama ; Sutter, Roland W. ; Grassly, Nicholas C.
• Description:
  In 2014, inactivated poliovirus vaccine (IPV) campaigns were implemented in Nigeria and Pakistan after clinical trials showed that IPV boosts intestinal immunity in children previously given oral poliovirus vaccine (OPV). We estimated the effect of these campaigns by using surveillance data collected during January 2014-April 2016. In Nigeria, campaigns with IPV and trivalent OPV (tOPV) substantially reduced the incidence of poliomyelitis caused by circulating serotype-2 vaccine-derived poliovirus (incidence rate ratio [IRR] 0.17 for 90 days after vs. 90 days before campaigns, 95% CI 0.04-0.78) and the prevalence of virus in environmental samples (prevalence ratio [PR] 0.16, 95% CI 0.02-1.33). Campaigns with tOPV alone resulted in similar reductions (IRR 0.59, 95% CI 0.18-1.97; PR 0.45, 95% CI 0.21-0.95). In Pakistan, the effect of IPV+tOPV campaigns on wild-type poliovirus was not significant. Results suggest that administration of IPV alongside OPV can decrease poliovirus transmission if high vaccine coverage is achieved.
• Subjects:
  Female Geography, Medical History, 21st Century Humans Immunization Programs Incidence Male Outcome Assessment (Health Care) Poliomyelitis/epidemiology Poliomyelitis/history Poliomyelitis/prevention & Control Poliovirus Vaccine, Inactivated Prevalence Research Vaccination

  More +
• Source:
  Emerg Infect Dis. 23(2):258-263.
• Pubmed ID:
  27861118
• Pubmed Central ID:
  PMC5324799
• Document Type:
  Journal Article
• Place as Subject:
  Nigeria ; Pakistan
• Location:
  Africa ; Asia
• Volume:
  23
• Issue:
  2
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:7d04ec54377dadb7b8f2ebd4705aa738dd44585a4e3eb5be1f7edbe9e4f625bd
• Download URL:
  https://stacks.cdc.gov/view/cdc/44377/cdc_44377_DS1.pdf
• File Type:
  [PDF - 1.00 MB ]